Disc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria

Reuters

05-07

<a href="https://laohu8.com/S/IRON">Disc Medicine</a> Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria

Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria $(EPP.UK)$. This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application (NDA) in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera (PV) in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9445959-en) on May 07, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2533898420"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533898420\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2533898420?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533898420","market":"nz","top_or_hot":-1,"title":"Disc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a> Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria <a href=\"https://laohu8.com/S/EPP.UK\">$(EPP.UK)$</a>. This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application (NDA) in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera (PV) in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9445959-en) on May 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-07 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a> Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria <a href=\"https://laohu8.com/S/EPP.UK\">$(EPP.UK)$</a>. This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application (NDA) in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera (PV) in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9445959-en) on May 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nNDL3xFDlR:1","article_id":"2533898420","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533898420","pubTimestamp":1746619314,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria . This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application  in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera  in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IRON":"Disc Medicine","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Disc Medicine Inc.启动Bitopertin治疗红细胞生成性原卟啉症的APOLLO试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRON":0.9,"NDAQ":0.9},"content_text":"Disc Medicine Inc. Launches APOLLO Trial for Bitopertin in Treatment of Erythropoietic Protoporphyria\n    \n\n        Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria $(EPP.UK)$. This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application (NDA) in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera (PV) in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9445959-en) on May 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}